Jae Hyug Kim

Learn More
OBJECTIVES In recent years, BRAF(V600E) mutation has emerged as a promising prognostic marker for risk stratification of patients with papillary thyroid carcinoma (PTC). However, routine use of this marker has been questioned. In some parts of the world, particularly in Korea, the incidence of BRAF(V600E) mutation is too high to have true prognostic value.(More)
BACKGROUND The relationship between Hashimoto's thyroiditis (HT) and papillary thyroid cancer (PTC) with regard to their co-occurrence and the effect of concurrent HT on the prognosis of PTC has been debated. The aim of the present study is to determine a clinical relationship between these two disease entities and to evaluate the correlation between(More)
Persistent pulmonary hypertension (PPHN) of the newborn remains a challenging condition to diagnose and treat. It has been reported in infants with Smith-Lemli-Opitz syndrome (SLOS), a rare defect in cholesterol synthesis. Typically, there is evidence of pulmonary hypoplasia. We report the first case of PPHN in the absence of pulmonary hypoplasia or other(More)
Received November 29, 2011 / Revised 1st March 5, 2012, 2nd April 3, 2012 / Accepted April 12, 2012 Correspondence: Jin Ho Sohn, MD, PhD, Department of Otolaryngology-Head and Neck Surgery, Kyungpook National University Hospital, 50 Samduck 2-ga, Jung-gu, Daegu 700-712, Korea Tel: 82-53-200-5777, Fax: 82-53-423-4524, E-mail: Jinho Sohn@knu.ac.kr Inadvertent(More)
Concurrent chemoradiotherapy has become the standard of care for advanced head and neck cancers in organ preservation strategies. However, the optimal regimen for concurrent chemoradiotherapy to maximise treatment response and minimise toxicity has not been determined. The purpose of the present clinical study was to review our experience with concurrent(More)
A combination of 5-fluorouracil and cisplatin (FP regimen) is widely used as a standard treatment for head and neck cancer. Recently, capecitabine has received increased attention. We conducted a retrospective study to compare the efficacy and safety of the FP regimen with that of the "XP regimen," which entails concurrent chemoradiotherapy (CCRT) with(More)
  • 1